Elementis (LSE:ELM) is sharpening its focus on specialty additives by selling businesses that do not fit, concentrating on two markets, personal care and coatings, where its rheology modifiers and other ingredients earn high margins, and returning surplus cash to shareholders. The latest step came on 2 June 2026, when it completed the sale of its pharmaceutical Manufacturing Business to Associated British Foods and launched a share buyback of about $35m funded by the proceeds.

The results are starting to show. In its half-year results for the six months to 30 June 2026, published on 30 July, Elementis reported Revenue up 9.4 per cent to $318.2m, organic constant-currency growth of 4.7 per cent, and an adjusted operating Margin of 23.0 per cent, up from 21.6 per cent a year earlier. That already matches the medium-term margin target of 23 per cent or more set under the "Elevate Elementis" strategy.

Chief executive Luc van Ravenstein said the group was seeing "real progress coming through in our financial results". The shares rose close to 4 per cent on results day.

What Elementis Actually Makes

Elementis is a specialty chemicals company whose products change how other products look, feel and behave. Its best-known ingredient is hectorite, a naturally occurring clay used as a thickener and stabiliser in cosmetics, skincare and paints. It also makes rheology modifiers and additives for industrial and decorative coatings, and supplies an energy business within its coatings segment.

After the pharmaceutical disposal, the group reports two segments. In the first half of 2026, Personal Care generated revenue of $109.2m, up 2.9 per cent organically, with an adjusted Operating Margin of 38.1 per cent. Coatings produced $209.0m of revenue, up 5.6 per cent organically, at a margin of 20.7 per cent.

From Talc to Pharma: A Slimmer Portfolio

The simplification has been steady. Elementis completed the sale of its talc business in May 2025, booking a loss on sale of $110.5m against net cash proceeds of $52.5m, according to its FY2025 preliminary results. It then agreed the pharmaceutical sale in March 2026 at an Enterprise value of €34.3m and completed it on 2 June, generating around $36m of net cash proceeds and a $13.0m book gain.

The company says the disposals reposition it as a "pure-play specialty chemicals leader" focused on value-added additives. The pharmaceutical business had contributed around $35m of revenue in 2025, so its removal trims the Top Line but lifts group margins and reduces Capital intensity.

The group has also bolted on capability. In November 2025 it acquired Alchemy, a maker of natural skincare rheology modifiers, for an enterprise value of $22m. Management said on the half-year call that the business was performing well.

Inside "Elevate Elementis"

Launched in July 2025, shortly after van Ravenstein's appointment as chief executive in April that year, the strategy rests on three priorities: accelerating sustainable growth, becoming the first choice for customers, and building a "simpler, leaner Elementis".

Its medium-term targets are mid-single-digit revenue growth through the cycle, an adjusted operating margin of 23 per cent or more, three-year operating cash conversion above 90 per cent and a return on capital employed, excluding goodwill, above 30 per cent.

Innovation is central. Elementis says hectorite penetration in personal care has reached around 50 per cent, and launches of skincare and suncare products using its ingredients rose 25 per cent in the first half. In coatings, management pointed to new applications, including wire protection and defence products, and expansion in Asia, with Volume rather than price driving most of the growth.

Self-help is the other lever. The company says it has achieved $6.5m of a $10m cost-savings target since the strategy began, with on-time, in-full delivery improving to 88 per cent from 83 per cent at the end of 2025.

Cash, Dividends and the Balance Sheet

For the full year to 31 December 2025, Elementis reported revenue of $597.5m, adjusted operating profit of $126.7m and a margin of 21.2 per cent. Adjusted Diluted Earnings per Share rose 14.2 per cent to 13.7 cents, and the full-year Dividend increased 7.5 per cent to 4.3 cents. It also completed $53.8m of share Buybacks during 2025.

In the first half of 2026, adjusted diluted EPS jumped 28.8 per cent to 8.5 cents and the Interim Dividend rose 15.4 per cent to 1.5 cents. Net Debt fell to $163.8m from $185.4m at the end of 2025, equivalent to 1.1 times EBITDA. Management said on the call that it continues to assess bolt-on acquisitions while keeping around 1.0 times Leverage in view.

Free Cash Flow is one area to watch. It fell to $13.3m in the first half from $15.4m a year earlier, following a decline to $41.0m in 2025 from $51.0m in 2024.

What Could Blunt the Edge

Demand remains the main uncertainty. Management described the macroeconomic environment on the results call as "still very uncertain" and noted that consumer spending was "still not great", although it saw no sequential weakening into the second half and a solid order book for the third quarter. The FY2025 results flagged soft Demand for coatings and US Tariff Volatility as headwinds.

Management also expects margins to moderate in the second half because of the usual seasonal weighting towards the first six months. Having hit its 23 per cent target in a strong half, Elementis will need to show it can hold margins at that level over a full cycle. Currency movements, raw material costs and the integration of acquisitions add further variables.

Looking Ahead

Elementis said it remains "confident in delivering full year performance in line with expectations", citing company-compiled consensus for 2026 adjusted operating profit of $132.5m, within a range of $129.4m to $136.5m. The next checkpoints are progress on the $35m buyback, which has generated regular transaction-in-own-shares announcements, a trading update in the new year and the full-year results for 2026, expected in early 2027 if the usual timetable holds. Christine Soden was confirmed as senior independent director on 16 September 2026.

Summing Up

Elementis has turned itself into a more focused specialty additives business, and the first half of 2026 suggests the approach is working: stronger margins, higher earnings per share, lower debt and a buyback under way. The Balance Sheet gives room for bolt-on deals. Against that, coatings demand is soft, free cash flow has slipped and second-half margins are expected to ease, so the durability of the improvement through a full economic cycle is still to be proven.